DRREDDY
Dr. Reddy’s Laboratories Limited Q4 & FY26 Results Update: Strong Financial Performance and Strategic Milestones
Dr. Reddy’s Laboratories Limited DRREDDY reports strong Q4 & FY26 results with double-digit growth and strategic milestones.
Dr. Reddy’s Laboratories Limited (DRREDDY) has unveiled its Q4 and FY26 results, showcasing robust financial performance and significant strategic milestones. The company reported a 12% year-over-year growth in revenues to ₹7,516 Cr for Q4 FY26, driven by double-digit base business growth and strategic acquisitions. Notably, EBITDA stood at ₹981 Cr, marking a 13% increase year-over-year. PBT and PAT also saw substantial growth, reaching ₹199 Cr and ₹220 Cr respectively.
Financial Highlights
Excluding specific items, the company’s RoCE improved to 17.5%, and net cash surplus stood at ₹3,271 Cr. For the full fiscal year, revenues grew by 3% to ₹33,593 Cr, with EBITDA, PBT, and PAT rising to ₹7,659 Cr, ₹5,482 Cr, and ₹4,285 Cr respectively.
Strategic Milestones
Dr. Reddy’s Laboratories Limited achieved several strategic milestones during the period. The company became the first to secure approval for a generic semaglutide injection for Type 2 Diabetes in Canada and launched the same under the brand name ‘Obeda®’ in India. Additionally, the company secured approval for generic semaglutide tablets in India and had its abatacept biosimilar (IV) BLA accepted for review by the USFDA.
The company also expanded its portfolio by acquiring Progynova® and Cyclo-Progynova® in India for Hormone Replacement Therapy and completed the integration of 95% of the acquired NRT business by value as of March 2026.
Dr. Reddy’s Laboratories Limited continues to focus on sustainable growth and was recognized with a Gold Medal by EcoVadis for FY26, achieving its highest-ever score of 80, placing it among the top 5% of companies assessed globally.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. The PEG of 0.55 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 14.9% and profits at 33.9% CAGR. The market consistently rewards this kind of compounding. The stock gains 3.1% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Both the business and the stock move in the right direction. Revenue grows at 14.9%, profits at 33.9%, and the PEG sits at 0.55 — below its growth rate. That combination is rare. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited Receives Marketing Authorization for Generic Semaglutide Injection in Brazil
Dr. Reddy’s Laboratories Limited (DRREDDY) secures marketing authorization for generic semaglutide injection in Brazil, expanding its diabetes treatment opti.
Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) announced today that Brazil’s National Health Surveillance Agency (ANVISA) has granted marketing authorization for its generic semaglutide injection. This approval allows Dr. Reddy’s to offer the treatment for adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. The product will be available as a pre-filled, multi-dose injectable pen in two presentations, 2 mg/1.5 mL and 4 mg/3 mL, for once-weekly dosing.
Significant Market Expansion
This authorization marks a significant step for Dr. Reddy’s in expanding its semaglutide presence to Brazil, one of the key markets in Latin America. Brazil has 16.6 million adults aged 20–79 living with diabetes, ranking sixth globally in terms of the number of adults living with diabetes. The semaglutide market for diabetes in Brazil is estimated at approximately USD 244.6 million.
Strategic Growth
Commenting on the approval, MV Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said, “Our focus with semaglutide is to expand access to this treatment option across markets where the patient need is significant. Brazil, with its substantial burden of diabetes, is an important part of that journey. This approval builds on our broader semaglutide strategy and brings us another step closer to making semaglutide available to more patients. We plan to launch semaglutide in Brazil with Aché.”
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company is committed to providing access to affordable and innovative medicines. Driven by its purpose of ‘Good Health Can’t Wait,’ Dr. Reddy’s offers a portfolio of products and services including APIs, generics, branded generics, biosimilars, and OTC. The company’s major therapeutic areas of focus include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. As a company with a history of deep science, Dr. Reddy’s continues to invest in businesses of the future and remains an early adopter of sustainability and ESG actions.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited Q2fy27 Results Update: Double-digit Growth, Strong Financials
Dr. Reddy’s Laboratories Limited DRREDDY reports double-digit Q2FY27 growth, with ₹8,671 Cr revenue and 20.6% EBITDA margin.
Dr. Reddy’s Laboratories Limited (DRREDDY) showcased robust financial performance for Q2FY27, as per consolidated financial statements under IFRS. The company reported a revenue of ₹8,671 Cr, marking a 1.5% year-on-year growth. The EBITDA margin stood at 20.6%, reflecting consistent double-digit base business growth. The company’s progress across strategic priorities highlights its commitment to innovation and market expansion.
Financial Highlights
The financial highlights for Q2FY27 include a reported EBITDA of ₹1,783 Cr, a 24% year-on-year increase. The PBT reached ₹1,228 Cr, up 33% YoY, and PAT stood at ₹925 Cr, with a 36% YoY growth. Notably, the RoCE was annualized at 9.5%, and the net cash surplus stood at ₹2,502 Cr.
Strategic Initiatives
Dr. Reddy’s Laboratories Limited has made significant strides in its strategic initiatives. The company partnered with Takeda for India’s first CDSCO approved dengue vaccine, QDENGA, set to launch in private markets in H1 2027. Additionally, collaborations with Gilead Sciences and GARDP Foundation have expanded its global footprint.
The company also secured approval for rituximab biosimilar from the USFDA and launched nivolumab biosimilar in India. Furthermore, generic semaglutide has been approved in 10 countries across Latin America, Africa & the Middle East, as well as Canada & India.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited (NSE: Drreddy) Receives DCGI Approval for Zytorvi® in Advanced Esophageal Squamous Cell Carcinoma
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced DCGI approval for Zytorvi® in advanced esophageal squamous cell carcinoma.
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced today that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks the second approved indication for Zytorvi® in India, expanding its use beyond its initial approval in nasopharyngeal carcinoma (NPC).
Expanding Access to Immunotherapy
Through this approval, Dr. Reddy’s Laboratories Ltd. aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India. The approval is supported by the results from the Phase 3 JUPITER-06 trial, which demonstrated a 42% reduction in the risk of disease or death compared with chemotherapy alone.
Significant Market Opportunity
In 2024, esophageal cancer was the fourth leading cause of cancer-related death in India, accounting for approximately 8.1% of all cancer deaths. ESCC, the predominant subtype, accounts for approximately 80% of all esophageal cancer cases in India. With this approval, Dr. Reddy’s Laboratories Ltd. is taking a significant step in addressing this critical need.
M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said: “Following the approval of Zytorvi® in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
-
AFFORDABLE3 days agoAffordable Robotic & Automation Limited Secures ₹19 Crore Order for Next-gen Agv-based Car Parking Technology
-
Healthcare3 days agoMorepen Laboratories Limited Launches Desloratadine Tablets in U.S. Prescription Market
-
Credit Services2 days agoMoneyboxx Finance Limited (moneyboxx): Q2 FY27 Pre-provision Operating Profit Up 79% Yoy and 4x
-
Consumer Cyclical2 days agoWhirlpool of India Limited (whirlpool) Delivers Double Digit Revenue Growth in Q2 Fy26-27
-
Basic Materials3 days agoShyam Metalics and Energy Limited (shyammetl) Reaffirms Credit Ratings and Enhances Bank Debt
-
Industrials2 days agoPower & Instrumentation (gujarat) Limited (pigl) Q2 FY27: Ebitda Jumps 45%, Orders Surge
-
HIRECT1 day agoHirect Limited Q2 & H1 FY27: Highest-ever Revenue, Strong Business Momentum
-
Consumer Cyclical1 day agoKalyan Jewellers India Limited (kalyankjil) Q2 FY27: Revenue Surpasses Rs 10,300 Crore, PAT Rises 64%